Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 3/20 | 0.38 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.37 |
| ▸ | VCP | P55072 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7232975 | 0.88 | SNCA (0.43) | SNCAACHEBACE1USP28HTR1D | |
| SCHEMBL7228891 | 0.88 | CYP2D6 (0.46) | SNCABACE1CASRUSP28POLB | |
| SCHEMBL7224328 | 0.86 | SNCA (0.45) | SNCABACE1POLB | |
| SCHEMBL7223887 | 0.86 | SNCA (0.43) | SNCAACHEBACE1POLB | |
| SCHEMBL7231636 | 0.84 | SNCA (0.40) | SNCABACE1CASRPOLB | |
| SCHEMBL7224364 | 0.78 | HAT1 (0.47) | SNCAPOLB | |
| SCHEMBL7232847 | 0.78 | HAT1 (0.52) | SNCAACHEHTR1DHTR1B | |
| SCHEMBL7222496 | 0.78 | TRPV1 (0.46) | SNCA | |
| SCHEMBL7230814 | 0.76 | HRH3 (0.44) | SNCAACHE | |
| SCHEMBL7231188 | 0.76 | F10 (0.47) | SNCAACHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | claimed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | claimed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | SNCA 2451/4885ACHE 681/4885BACE1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.